Biomarkers and mathematical models for prognosis and prediction in brain metastasis (METMATH)

Brain metastases (BMs) are cells that spread to the brain from tumors in other organs. A proportion of 10% – 35% of adult cancer patients develop BMs. Estimating prognosis among patients with BMs is clinically relevant, as it allows the recommendation of treatments to balance durability of intracranial tumor control

Where is it being implemented?

The protocol has been approved and is running at MD Anderson Cancer Center (Madrid), Hospital Universitario de Salamanca, Hospital Regional Universitario de Málaga and Instituto Valenciano de Oncología (Valencia). It is being considered for implementation in other hospitals.

What data do we collect?

Our collaborators collect retrospective data from the primary tumor and BMs, clinical data, and the whole MRI longitudinal imaging dataset (all sequences available for diagnosis, radiosurgery planning, and follow-up) obtained with the best possible resolution in clinical routine.

What are the expected benefits for patients?

The idea is to explore whether novel mathematical algorithms can be used to develop prognoses and predictive biomarkers based on the data, and also, to anticipate or identify radiation necrosis events.

When will the results be available?

Data collection has already started and will be completed during 2019. We expect to have initial results by the end of 2019 and continue obtaining results for several years.